Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01252589 · ClinicalTrials.gov registry record
Patient Reported Outcomes in Chronic Myeloid Leukemia
A clinical trial of Chronic Myeloid Leukemia, sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto.
- Completed
- Registry status
- 480
- Enrollment target
- 14
- Study locations
NCT01252589: Completed study of Chronic Myeloid Leukemia, sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto.
NCT01252589 is a study of Chronic Myeloid Leukemia that has completed, run by Gruppo Italiano Malattie EMatologiche dell'Adulto. The registered enrollment target is 480 participants, above the 196-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (145% higher). The trial reports 14 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01252589, a study of Chronic Myeloid Leukemia, has completed, sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto.
- COMPLETED
- Registry status
- 480 participants
- Enrollment target
- 14
- Study locations
Study Summary
Although the impact of disease and treatment related burden on health-related quality of life (HRQOL) in patients with solid tumours has been well studied, with several clinical trials that included HRQOL as an endpoint, the general understanding in patients with Chronic Myeloid Leukaemia (CML) is lacking in comparison. The literature shows that patients' perspective is unique and should always be measured with methodologically sound instruments that are devised for this purpose. The main scope of this project is develop to an international validated questionnaire for the purpose of HRQOL assessment; such a tool will then be used to provide important data, from the patients' perspective, to make more informed treatment decisions.
Conditions Studied
Interventions
- OTHER HRQOL questionnaire
Study Locations (14)
Other
- Innsbruck University Hospital - Innsbruck
- University of Ghent - Ghent
- Centre Hospitalier Universitaire of Poitiers - Poitiers
- University of Heidelberg - Heidelberg
- University of Athens - Athens
- University of Baghdad - Baghdad
- Policlinico S. Orsola - Malpighi, Università di Bologna - Bologna
- Ematologia Ospedale "Binaghi", Cagliari - Cagliari
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori- IRST - Meldola
- Ospedale S.Maria delle Croci - Ravenna
- Ematologia - Sapienza Università di Roma - Roma
- Tilburg University - Tilburg
- National Taiwan University - Taipei
Massachusetts
- Dana-Farber Cancer Institute Harvard University - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-09 |
What the finished NCT01252589 record still lists
NCT01252589 is an observational study that tracks outcomes without assigning an intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, above the 196-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (145% higher).
The record links to 1 condition, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which HRQOL questionnaire is the first listed.
NCT01252589 lists 14 locations in 2 states (Other, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT01252589 about?
NCT01252589 is a clinical study titled "Patient Reported Outcomes in Chronic Myeloid Leukemia". Although the impact of disease and treatment related burden on health-related quality of life (HRQOL) in patients with solid tumours has been well studied, with several clinical trials that included HRQOL as an endpoint, the general understanding in patients with Chronic Myeloid Leukaemia (CML) is l...
What is the current status of trial NCT01252589?
This trial is currently completed. The enrollment target is 480 participants. The study started on 2010-11. Estimated completion is 2013-09.
What conditions does trial NCT01252589 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia.
What interventions are being tested in trial NCT01252589?
The interventions under investigation include: HRQOL questionnaire (OTHER).
Who is sponsoring clinical trial NCT01252589?
This trial is sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01252589 being conducted?
This trial has 14 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01252589's enrollment target sits among peer trials
480 3rd of 35 higher than 33 of 35 other Chronic Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RECRUITING · Phase 1
-
Study of Olverembatinib (HQP1351) in Patients With CP-CML
RECRUITING · Phase 3
-
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
RECRUITING · Phase 2
-
KRT-232 and TKI Study in Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia